Biomarin Pharmaceuticals
(BMRN)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2021 | 09-2021 | 06-2021 | 03-2021 | 12-2020 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 587,276 | 617,143 | 641,533 | 667,313 | 649,158 |
| Marketable Securities | 426,599 | 462,333 | 481,864 | 420,178 | 416,228 |
| Receivables | 373,399 | 374,937 | 424,419 | 396,097 | 448,351 |
| Inventories | 776,669 | 749,406 | 710,975 | 713,929 | 698,548 |
| Other current assets | 110,442 | 107,751 | 99,046 | 91,249 | 129,934 |
| TOTAL | $2,274,385 | $2,311,570 | $2,357,837 | $2,288,766 | $2,342,219 |
| Non-Current Assets | |||||
| PPE Net | 1,035,461 | 1,024,787 | 1,026,579 | 1,022,474 | 1,032,471 |
| Investments And Advances | 507,793 | 466,618 | 350,237 | 321,127 | 285,473 |
| Intangibles | 584,851 | 584,686 | 590,497 | 602,102 | 613,470 |
| Other Non-Current Assets | 1,602,282 | 1,589,814 | 1,573,346 | 1,570,584 | 1,574,387 |
| TOTAL | $3,730,387 | $3,665,905 | $3,540,659 | $3,516,287 | $3,505,801 |
| Total Assets | $6,004,772 | $5,977,475 | $5,898,496 | $5,805,053 | $5,848,020 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 546,497 | 514,898 | 443,344 | 430,035 | 492,548 |
| TOTAL | $546,497 | $514,898 | $443,344 | $430,035 | $492,548 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 1,192,606 | 1,196,428 | 1,213,581 | 1,213,008 | 1,249,470 |
| TOTAL | $1,192,606 | $1,196,428 | $1,213,581 | $1,213,008 | $1,249,470 |
| Total Liabilities | $1,739,103 | $1,711,326 | $1,656,925 | $1,643,043 | $1,742,018 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 184,032 | 183,593 | 183,352 | 182,743 | 181,830 |
| Common Shares | 184 | 184 | 183 | 183 | 182 |
| Retained earnings | -930,760 | -867,791 | -831,297 | -844,238 | -861,609 |
| Other shareholders' equity | 4,743 | 14 | -11,146 | -4,554 | -25,978 |
| TOTAL | $4,265,669 | $4,266,149 | $4,241,571 | $4,162,010 | $4,106,002 |
| Total Liabilities And Equity | $6,004,772 | $5,977,475 | $5,898,496 | $5,805,053 | $5,848,020 |